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Abstract
Equine encephalosis virus (EEV) distribution was thought to be limited to southern Africa until 2008 when we reported EEV
in Israel. It was then assumed that the clinical presentation resembled the initial incursion in Israel. To investigate further we
conducted a retrospective analysis of equine sera, which had been collected for diagnosis of other suspected diseases, via
serum neutralisation test. The data demonstrated that EEV was circulating as early as 2001 with incidence ranging from 20–
100% for time period 2001–2008. As the symptoms of EEV can be similar to other equine notifiable diseases this is a
significant finding which highlights the need for vigilance and education to accurately diagnose new and emerging
diseases.
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Introduction
Equine encephalosis virus (EEV) is an Orbivirus, family
Reoviridae. The genome consists of 10 double stranded RNA
segments of which the second segment (VP2) can used to
determine serotype [1] To date; seven antigenically distinct
serotypes of EEV have been identified [2]. EEV is an acute
arthropod-borne viral infection that infects all species of equids
and is transmitted by certain Culicoides species. It was first isolated
in South Africa in 1967 and is thought to be endemic in this
region. Until 2008 and its appearance in Israel [3], EEV
distribution was thought to be limited to southern Africa.
Recently, a serological study reported the virus to be endemic in
countries of East and West Africa [4].
Some of the symptoms observed in cases of EEV are common
to cases of other notifiable diseases, particularly African Horse
Sickness (AHS) and Equine Viral Arteritis (EVA) making EEV
important as a differential diagnosis [2]. We reported an
undiagnosed disease in several horses in four stables in the
Hamerkaz region in central Israel from an outbreak which
started in October 2008 [3]. Symptoms included fever (up to
41uC), depression, anorexia, edema, muscle pain, stiffness,
generalised weakness, cough and in some cases nasal discharge
and conjuctivitis. In the following three weeks the disease spread
throughout the country with 42 recorded outbreaks and an
estimated 80% of the country’s horse population effected. The
disease affected all breeds, ages and sexes. Ninety percent of
horses recovered from the disease without additional complica-
tions and no deaths were reported. Initially, the disease was
thought to be EVA but serological tests for this, influenza,
equine rhinopneumonitis and West Nile virus all gave negative
results. Additional tests for toga and flavi viruses were also
negative. The causative agent was finally identified as EEV
following DNA array analysis, with subsequent RT-PCR and
sequence analysis [3]. As EEV disease symptoms could be easily
confused with that of other viruses it was of interest to
investigate whether this was truly the first incursion or whether
EEV had been circulating previously in Israel. To undertake
this objective we conducted retrospective serological analysis of
equine serum samples from Israel dating back to 2001. In
addition we undertook full genome sequencing of an isolate
obtained from the beginning of the 2008–9 outbreak in order to
gain a deeper understanding with regards to origin of the Israeli
outbreak.
Materials and Methods
Sample selection for retrospective serological analysis
Samples were selected from archived material which was
submitted to the Kimron Veterinary Institute during the period
2001–2008 for diagnosis of other suspected diseases, but for
which a laboratory diagnosis was not reached. The samples
were selected on basis that clinical examination suggested
symptoms associated with notifiable diseases. The investigated
samples were from foals (9.2%), geldings (45.4%), mares (42.9%)
and stallions (2.5%). Over 50% of the samples were from horses
housed along the Mediterranean Coast with the remainder
originating from various in-land regions across northern Israel.
Symptoms observed in the sample set included respiratory,
neurological and reproductive (abortions). None of the sampled
animals had travelled outside of Israel. Sample collection was
conducted according to the animal welfare committee guidelines
of the Kimron Veterinary Institute, which also approved the use
of the samples for this study.
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EEV Virus Isolation
1 ml of blood was inoculated onto 1 day old 25 cm2 flask of
Vero cells (ATCC) at 90% confluent monolayers. The flasks were
incubated for 1 hour at 37uC in 5% CO2 to allow the virus to
adsorb and then the inoculums washed off and overlaid with 10 ml
of MEM supplemented with 5% fetal bovine serum (Life
Technologies, UK). The cultures were examined daily for up to
5 days incubation, before being harvested by freeze/thawing and
passaging onto fresh cell cultures.
Virus neutralisation assay
The virus neutralisation assay was essentially that described by
Senne et al. [5], for EVA except that rabbit complement was not
was included in the addition of EEV. To conduct serological
analysis, a virus isolate from the beginning of the 2008–9 outbreak,
Kimron1, was cultured and titred to determine the TCID50 per
ml. Serial twofold dilutions of the test sera (heat treated at 56uC for
30 minutes for complement inactivation) were made in duplicate
in serum free cell-culture medium using a 96-well microtitre plate
starting at a 1:2 serum dilution. Using serum-free cell culture
medium as a diluent, a dilution of stock virus was prepared
containing 100 TCID50/ml. A virus back titration of the working
dilution of stock virus was included with each test. The plates were
incubated for 1 hour at 37uC in a humid atmosphere of 5% CO2
in air. A suspension of Vero cells was added and the plates were
returned to the incubator for 3–5 days before reading for
cytopathic effect. To obtain a more accurate reading of the titre
end-points an immunoperoxidase stain was performed as de-
scribed by Smith et al., [6]. End points were calculated using the
Spearman-Ka¨rber method [7].
Full genome sequencing and analysis
The Kimron1 isolate was used as the starting material for next
generation sequencing via the Roche 454 FLX platform following
protocols described by Ramussen et al., 2008 and 2010 [8–9].
Additional sequences were obtained from GenBank for compar-
ison. Nucleotide alignments were conducted using Clustal W [10].
Results and Discussion
The serological analysis revealed antibody positives in each year
analysed back to 2001 (Table 1). The percentage varied between
20–100%, however these data should only be seen as demon-
strating previous infection as this study was not designed as an
epidemiological survey.
The resultant full genome sequence of Kimron1 (accession:
AB811630-9) was compared to other publicly available EEV
sequences. Here, we were limited as full genome data is only
available for one other EEV strain HS103/06 Bryanston
(accession FJ183384-93). In comparison to HS103/06 the
greatest diversity was observed in comparison of the VP2 gene
(54% at the nucleotide level) and greatest similarity was
observed in comparison of the VP7 gene (96% at the
nucleotide level). Analysis of other VP2 sequences revealed
closest similarities to Kaalpaas serotype 3 strain (92% at a
nucleotide level), Israeli isolates from 2008–9 outbreak
described by Aahronson-Raz et al. [11], (99.8% homology)
and a Gambian isolate from 2009 described by Oura et al. [4],
(99% nucleotide homology) (accession: HQ630933, JF495411,
JF495412 and JN391443 respectively). Analysis of the NS3
revealed 99.9% homology with a 2009 Israeli isolate [11]
(accession: HQ441245). Further investigation into genetic
origin was not possible due to lack of sequence data for
comparison. We attempted genomic amplification on the
samples used in the retrospective serological analysis; this was
unsuccessful with alternate samples from the same animals not
being available.
The similarity in the clinical presentation of EEV with other
notifiable diseases, particularly EVA, is demonstrated by the
symptoms and history of the 2008–9 outbreak. The detection of
EEV outside of Africa highlights the risk of its spread to other
regions where susceptible animals and suitable vectors are
present, it is thus essential to understand the distribution of
EEV. Here we demonstrate that a very similar strain of EEV,
belonging to the same serotype, was already circulating in the
Mediterranean region during a time period in which it was
thought that the virus circulation was limited to southern Africa.
None of the animals investigated had travelled outside of Israel
therefore infection must have been acquired in country. From
2001 onwards at least, EEV infection was either overlooked or
mis-diagnosed: demonstrating both the importance of vigilance
and education to diagnose new and emerging diseases with the
assistance of laboratories equipped to carry out investigative
virology.
Full genome sequence data will be of interest to those wishing to
undertake further investigation of this disease. As EEV has a
segmented genome it would be of interest to investigate whether
recombination events contributed to the virulent strain observed in
the 2008–9 Israeli outbreak. The similarity of the Israeli VP2
sequences to the 2009 Gambian isolate [4] may provide inference
regarding the origin of the Israeli outbreak however thus far a lack
of sequence data prevents further analysis, highlighting the need of
additional sequencing if EEV is to be accurately analysed in its
temporal and spatial distribution.
Table 1. Serological analysis for EEV antibodies in Israeli equine sera 2001–2008.
Sample date (Year) Number of samples tested Number of positives Percentage positive
2001 5 4 80
2002 5 1 20
2003 5 5 100
2004 5 2 40
2005 5 1 20
2006 10 3 30
2007 8 3 37.5
2008 76 57 75
doi:10.1371/journal.pone.0070532.t001
EEV in Israel
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